Trump Governance’s Push to Align US Vaccine Schedule with Denmark’s Sparks Public Health Concerns
A recent move by the U.S. Centers for Disease Control and Prevention (CDC) to reconsider the universal hepatitis B vaccine recommendation for newborns, coupled with a directive from President Donald Trump to align the U.S. vaccination schedule with countries like Denmark, has ignited a debate among public health experts. The core issue? A essential mismatch between the healthcare systems and disease burdens of the U.S. and Denmark makes a direct comparison – and potential alignment – deeply problematic.
The controversy began with a vote by the CDC’s Advisory Committee on Immunization Practices (ACIP) to potentially remove the long-standing recommendation for a first dose of the hepatitis B vaccine at birth. This decision, widely criticized by public health professionals, stems from a belief that the benefits of universal vaccination may not outweigh the risks for infants born to mothers who test negative for the virus.However, experts argue that such a shift in policy fails to account for the notable differences between the two nations and that we should expect country-level policy decisions to vary.
The sheer scale of the two nations is a primary factor. The U.S. boasts a population exceeding 340 million, while Denmark’s population is just over six million. Beyond size,the countries differ significantly in demographic and economic homogeneity. Crucially, they also face vastly different disease burdens. In 2023, Denmark reported 99 new cases of chronic hepatitis B, a stark contrast to the over 17,000 new cases recorded in the U.S.
This disparity in disease prevalence is further compounded by differences in screening and treatment protocols. Denmark routinely screens nearly all pregnant individuals for hepatitis B, with the majority of those testing positive receiving treatment. In the U.S., approximately 85 percent of pregnant people are screened, but many do not receive necessary treatment. Hepatitis B, a potentially fatal liver infection, can lead to cirrhosis, liver cancer, and death if left untreated.
The fundamental difference in healthcare systems is perhaps the most significant obstacle to a meaningful comparison. The U.S. system relies heavily on privately funded insurance,with Medicare and Medicaid providing coverage for specific populations.Denmark, conversely, operates a universal healthcare system funded by the government, ensuring access to free care for all residents. “Managing and following a small population with universal health care is much different than an enormous population with multiple delivery systems and multiple payers,” explained Kathryn Edwards, a professor of pediatrics at Vanderbilt University Medical Center. “It’s like comparing apples and oranges.”
Jetelina echoed this sentiment, emphasizing that Denmark’s universal healthcare system minimizes the risk of individuals falling through the cracks, a common occurrence in the U.S. due to its fragmented healthcare capacity and lack of a comprehensive safety net.
Moreover, universal healthcare systems, like Denmark’s, frequently enough prioritize cost-effectiveness when determining vaccine recommendations. While vaccination is generally more cost-effective than treating the resulting diseases, budgetary considerations inevitably play a role.Such as, the United Kingdom, also with a state-funded universal healthcare system, does not routinely recommend flu vaccines for children, opting instead to prioritize older adults where the shots offer the greatest cost-benefit. This logic may partially explain Denmark’s approach to the hepatitis B vaccine.
The discussion at the December 5 ACIP meeting largely centered on hypothetical risks associated with the hepatitis B vaccine in infants born to individuals who test negative for the disease, with limited attention given to the broader societal benefits of widespread vaccination. Jetelina pointed out that the U.S. previously attempted a targeted vaccination strategy – vaccinating only those at high risk – prior to 1991. This approach proved ineffective, with thousands of children still contracting the infection through household transmission. Following the implementation of the universal birth dose in 1991,cases plummeted,with a 99 percent reduction in acute hepatitis cases among children,teens,and young adults by 2019.
this push to alter the U.S. hepatitis B vaccine recommendation aligns with a broader trend within the Trump administration and among many Republican lawmakers to prioritize individual freedoms over collective public health action.However, effective public health systems – and vaccination programs in particular – depend on collective action to protect vulnerable populations, including those with compromised immune systems, older adults, and young infants. “If we land too much on individualism, diseases are going to come back,” Jetelina warned.
The debate underscores the critical need to base public health policy on scientific evidence and a thorough understanding of the unique challenges and characteristics of the U.S. healthcare landscape, rather than attempting to replicate policies from countries with fundamentally different systems.
